logo
Plus   Neg
Share
Email

Amgen: FDA Approves Earlier Use Of Nplate To Treat Immune Thrombocytopenia

Amgen (AMGN) said the FDA has approved the Supplemental Biologics License Application (sBLA) for Nplate to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia. The updated indication expands treatment with Nplate to newly diagnosed and persistent adult immune thrombocytopenia patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

David Reese, executive vice president of Research and Development at Amgen, stated: "This approval will provide patients the opportunity to receive Nplate earlier in the course of their disease, potentially reducing their need for prolonged steroid use."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in... Google parent Alphabet Inc. has issued $5.75 billion in sustainability bonds, becoming the largest green or sustainability bonds issued by a company until now. This is part of a $10 billion debt offering. Alphabet said the proceeds will be used to fund projects that are environmentally or socially responsible.
Follow RTT